Coeptis Therapeutics, Inc. (formerly Vinings Holdings Inc.) conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc. (together “Coeptis”). Coeptis Therapeutics’ common stock is currently quoted on the OTC PINK under the symbol “COEP.” To see Coeptis Therapeutics, Inc.’s SEC filing please click on the SEC FILINGS link above.
Coeptis is a pharmaceutical company focused on the development of innovative therapeutics and technologies that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio consists of two clinical-stage drug candidates (CPT15050 and CPT60621) and the product opportunities through Coeptis’ two exclusive option agreements with VyGen-Bio, Inc., Inc. for co-development rights to a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers which are being developed by VyGen-Bio.
Coeptis’ business model is designed around commercializing and furthering the development of its current product portfolio and maximizing the portfolio’s value through in-license agreements, out-license agreements and co-development relationships, as well as other strategic partnerships in new and exciting therapeutic areas such as auto-immune disease and oncology. Additionally, Coeptis is actively targeting opportunities to expand its portfolio via partnerships with companies that have novel therapies in development or companies with technologies that improve the way that drugs are delivered to patients.